Private Group RLS (USA) Inc. Acquires GE Healthcare’s U.S. Radiopharmacy Network
RLS (USA) Inc., (Radioisotope Life Sciences) has purchased General Electric’s (GE) U.S. radiopharmacy network, making it the largest pure molecular imaging focused firm in the United States. Capitor, (www.capitor.co) a boutique global financial advisory firm, structured and brought the deal to investors, playing a critical part in the years-long negotiation and collaboration between the parties. Financial terms were not disclosed.
The radiopharmacies will continue to supply GE Healthcare molecular imaging products, with RLS leveraging a 10-year distribution partnership agreement. The now privately-owned radiopharmacy network includes a minority ownership by Perceptive Advisors, a $7 billion healthcare specialist investment firm based in New York.
The executive team of RLS is comprised of Chief Executive Officer Werner Gruner, Chief Investment Officer Jaco van Niekerk and Chief Operations Officer Shane Cobb. Mr. Gruner, who has served as executive in various roles within the international financial industry, including the founding of Capitor, comments that “I was intrigued and excited about the possibilities of this healthcare acquisition, beyond the financial aspects of the transaction. I have spent my career providing white-glove investment advisory services to global clients and always believed that customers, no matter the industry, not only deserve, but have a right to demand personalized, timely, high-end service,” adding, “that is why we focus on service, quality and disruptive technology as key factors in our investment strategy.”
The radiopharmacy network includes 31 pharmacies across 18 states, including its current headquarters in Tampa, Florida. Under the direction of Mr. van Niekerk, RLS aims to invest $2 billion over the next decade in expanding its footprint of pharmacies, while continuously investing in cutting-edge scientific and technological advancements. “We invested considerable efforts to ensure a seamless transition precisely because of our service-centric philosophy, including retaining key executive staff, such as Shane Cobb who has more than 30 years of experience in the industry,” stated Mr. van Niekerk, concluding that “RLS is committed to delivering life-saving quality diagnostics and treatment to patients across the nation. To that end, and in light of what we are uncovering regarding the potential long-term effects of organ damage caused by COVID-19, we have instituted a special task force focused on accommodating what could be a surge in demand for specialized diagnostic services.”
Almost five-hundred former GE employees across the country are now part of the RLS family. The company is expected to relocate its headquarters to the east coast of Florida in the near future and is in conversations with various economic development councils as well as municipalities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200901006104/en/
Contact information
Amanda Penebaker
608-345-9420
amanda.penebaker@rls.bio
https://rls.bio/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Equiduct Expands into the Swiss Market15.5.2025 09:00:00 EEST | Press release
Equiduct, the leading pan-European retail-focused exchange, today announced the launch of its Swiss equity segment, providing retail brokers using Apex with access to 138 of the most liquid Swiss-listed stocks — all priced in Swiss francs (CHF). The newly available securities include heavily traded household names such as Nestlé S.A., Novartis AG, UBS Group AG, and ABB Ltd. Liquidity on the Swiss segment of Equiduct is supported by Apex market makers Virtu Financial, Hudson River Trading, and Optiver. As with all executions on Equiduct, trades on the Swiss segment will benefit from fully interoperable clearing via Equiduct’s pan-European network of CCPs: LCH Ltd, Cboe Clear, and the local Swiss CCP SIX x-clear. This expansion follows formal approval from the Swiss Financial Market Supervisory Authority (FINMA), which recognises Börse Berlin and Equiduct as a regulated market under Article 41 of FinfraG. This status also paves the way for Swiss banks and brokers to join Equiduct as dire
Allianz Reports Record Operating Profit and Is Fully on Track to Achieve Full-Year Outlook15.5.2025 08:26:00 EEST | Press release
May 15, 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514121549/en/ Oliver Bäte, Chief Executive Officer of Allianz SE (Photo: Allianz SE) 1Q 2025 Total business volume advances 11.71 percent to 54.0 billion euros reflecting sustained momentum across all segments Operating profit increases 6.3 percent to 4.2 billion euros, reaching 26 percent of our full-year outlook midpoint Shareholders’ core net income is stable at a very good level of 2.6 billion euros. Adjusted for a one-off tax provision related to the forthcoming sale of our stake in our Indian Joint Ventures, shareholders’ core net income is up 5 percent Core earnings per share grow 2.9 percent and reach 6.61 euros. Adjusted for the above-mentioned one-off tax provision, core earnings per share are up 7 percent Annualized core RoE is robust at 16.6 percent, or 17.2 percent adjusted for the effect of the one-off tax provision Solvency II capitalization ratio
Corona Global Named Most Valuable Beer Brand in Kantar BrandZ Rankings for Second Consecutive Year15.5.2025 07:01:00 EEST | Press release
Corona has been recognized as the most valuable beer brand in the world for the second consecutive year in Kantar's BrandZ 2025 Most Valuable Global Brands report, released today. Eight out of the 10 most valuable global beer brands belong to AB InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD), according to the report ranking the top brands in the world. In 2024 AB InBev produced all-time high revenue and 15% Underlying EPS growth. The year marked double-digit growth for Corona outside of its home market of Mexico and triple-digit growth of its no-alcohol brand Corona Cero. Corona Cero is the first beer brand to sponsor the Olympic Games making its debut in Paris 2024. In 2025, Corona is celebrating its 100-year anniversary with events all over the world through its “Corona 100” platform. Corona is followed by Budweiser, the second most valuable beer brand in the world. Michelob ULTRA moved up one spot to #5 amongst beer brands globally. Michelob ULTRA has also been named the winner
Forrester Opens Nominations For Its 2025 B2B Awards In EMEA And APAC15.5.2025 07:00:00 EEST | Press release
Forrester (Nasdaq: FORR) today opened calls for nominations for its 2025 B2B Return On Integration Honors and B2B Programs Of The Year Awards in Asia Pacific (APAC) and Europe, Middle East, and Africa (EMEA). These awards will recognize B2B organizations based in both regions for achieving functional excellence and outstanding alignment across marketing, sales, and product — the B2B revenue engine — to improve customer experience and drive growth. Nominations for both award categories are open to organizations of all sizes in each region. B2B leaders across APAC and EMEA — including chief marketing officers, chief sales officers, chief product officers, and other marketing, sales, and product leaders — are invited and encouraged to apply. To be eligible, programs need to be developed by leaders and teams based in the APAC or EMEA regions. The nomination criteria for the two awards are as follows: B2B Return On Integration (ROI) Honors. These awards showcase organizations that have achi
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 05:12:00 EEST | Press release
Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often go undetected by conventional testing. In over 70% of cases, the test revealed findings, such as abnormalities in gut bacteria, signs of infection, markers of inflammation or insufficiency that could inform targeted treatment strategies. Further, two-thirds of MetaXplore patients in a separate study of follow up survey results reported improvement of symptoms after their care was guided by the test results. This press release features multimedia. View the full release here: https://www.businesswire.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom